| Subcribe via RSS



XOMA Regains NASDAQ Compliance

September 2nd, 2010

BERKELEY, Calif. — XOMA Ltd. , a leader in the discovery and development of therapeutic antibodies, today announced that NASDAQ has notified the Company that it regained compliance with the minimum $1.00 per share bid price requirement for continued listing.

Original post by macular degeneration – Google News


(click on the author/publication link above to see full post)
This entry was posted on Thursday, September 2nd, 2010 at 6:00 pm. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Comments are closed.

«
»